Lung Cancer
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...
Commentary
Neoadjuvant advantages: Treating locally advanced lung cancer
I think that it’s time to change some of our standards. When patients appear with lung cancers other than tiny ones that might be detected through...
News
This is how you get patients back for follow-up cancer testing
“What concerns me is that despite the various interventions implemented to encourage and support patients to return for follow-up testing, over 60...
Conference Coverage
Higher RT doses can boost lifespan, reduce risk of death in LS-SCLC patients
“We need more technical details to understand how to deliver this regimen in clinical practice, and it may not be applicable for all patients.”
Conference Coverage
Reducing cognitive impairment from SCLC brain metastases
Stereotactic radiosurgery was better at preventing loss of verbal recall function at 3 months than whole-brain radiation therapy, the current...
Latest News
These adverse events linked to improved cancer prognosis
Emerging evidence suggests that cutaneous immune-related adverse events may be linked with favorable outcomes among patients with cancer who...
Conference Coverage
Therapeutic vaccine shows promise in treating lung cancer
“We realized that just half of patients really benefited from the vaccine: those who had previously responded to immunotherapy.”
Commentary
New ‘C word’: Cure should be the goal for patients with lung cancer
I didn’t hear it at ASCO, but the truth of the matter is that’s a word we should be using and be using more.
News
Many patients with NSCLC receive immunotherapy ‘indefinitely’ – Are they benefiting?
Without “incontrovertible evidence” that immunotherapy should stop at 2 years, “many, many, many patients and clinicians are going to favor...
Conference Coverage
Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC
“Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a...
